Advertisement
PGEN vs VCYT
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PGEN is a Hold and VCYT is a Hold.
PGEN sees MACD Histogram just turned negative
PGEN saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 06, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 55 instances where the indicator turned negative. In 48 of the 55 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 87%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PGEN as a result. In 83 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
PGEN moved below its 50-day moving average on October 15, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for PGEN's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where PGEN advanced for three days, in 203 of 237 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
PGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 163 of 177 cases where PGEN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. PGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 86 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: PGEN's P/B Ratio (54.721) is slightly higher than the industry average of (2.835). P/E Ratio (-6.224) is within average values for comparable stocks, (-0.607). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.264) among similar stocks. P/S Ratio (32.258) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
VCYT in upward trend: 10-day moving average moved above 50-day moving average on October 02, 2026
The 10-day moving average for VCYT crossed bullishly above the 50-day moving average on October 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where VCYT's RSI Oscillator exited the oversold zone, 17 of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 66 cases where VCYT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
VCYT moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where VCYT advanced for three days, in 202 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VCYT as a result. In 86 of 106 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for VCYT turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 37 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VCYT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
VCYT broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for VCYT entered a downward trend on September 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating fairly steady price growth. VCYT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.536) is normal, around the industry mean (63.909). P/E Ratio (30.417) is within average values for comparable stocks, (1.606). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (5.583) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 75 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VCYT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
PGEN | VCYT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 29 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 93 Overvalued | 70 Overvalued | |
PROFIT vs RISK RATING 1..100 | 86 | 100 | |
SMR RATING 1..100 | 100 | 75 | |
PRICE GROWTH RATING 1..100 | 37 | 50 | |
P/E GROWTH RATING 1..100 | 22 | 95 | |
SEASONALITY SCORE 1..100 | 50 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VCYT's Valuation (70) in the Biotechnology industry is in the same range as PGEN (93) in the null industry. This means that VCYT’s stock grew similarly to PGEN’s over the last 12 months.
PGEN's Profit vs Risk Rating (86) in the null industry is in the same range as VCYT (100) in the Biotechnology industry. This means that PGEN’s stock grew similarly to VCYT’s over the last 12 months.
VCYT's SMR Rating (75) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that VCYT’s stock grew similarly to PGEN’s over the last 12 months.
PGEN's Price Growth Rating (37) in the null industry is in the same range as VCYT (50) in the Biotechnology industry. This means that PGEN’s stock grew similarly to VCYT’s over the last 12 months.
PGEN's P/E Growth Rating (22) in the null industry is significantly better than the same rating for VCYT (95) in the Biotechnology industry. This means that PGEN’s stock grew significantly faster than VCYT’s over the last 12 months.
| PGEN | VCYT | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 90% | 1 day ago 85% |
| Stochastic ODDS (%) | 4 days ago 86% | 1 day ago 88% |
| Momentum ODDS (%) | 4 days ago 86% | 1 day ago 81% |
| MACD ODDS (%) | 4 days ago 87% | 1 day ago 74% |
| TrendWeek ODDS (%) | 4 days ago 85% | 1 day ago 81% |
| TrendMonth ODDS (%) | 4 days ago 87% | 1 day ago 81% |
| Advances ODDS (%) | 11 days ago 86% | 5 days ago 73% |
| Declines ODDS (%) | 4 days ago 84% | 7 days ago 79% |
| BollingerBands ODDS (%) | 4 days ago 90% | 1 day ago 88% |
| Aroon ODDS (%) | 4 days ago 90% | 1 day ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PGEN’s FA Score shows that 0 FA rating(s) are green while VCYT’s FA Score has 0 green FA rating(s).
- PGEN’s FA Score: 0 green, 5 red.
- VCYT’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PGEN’s TA Score shows that 5 TA indicator(s) are bullish while VCYT’s TA Score has 5 bullish TA indicator(s).
- PGEN’s TA Score: 5 bullish, 4 bearish.
- VCYT’s TA Score: 5 bullish, 5 bearish.
Price Growth
PGEN (@Biotechnology) experienced а -13.05% price change this week, while VCYT (@Medical Specialties) price change was -0.50% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -7.86%. For the same industry, the average monthly price growth was -18.66%, and the average quarterly price growth was -19.56%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -4.01%. For the same industry, the average monthly price growth was -7.30%, and the average quarterly price growth was +34.04%.
Reported Earning Dates
PGEN is expected to report earnings on Nov 05, 2026.
VCYT is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Biotechnology (-7.86% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Medical Specialties (-4.01% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TGLR | 39.12 | 0.11 | +0.28% |
| Wedbush LAFFER TENGLER New Era Value ETF (TGLR) | |||
| DIVB | 68.63 | -0.17 | -0.25% |
| iShares Core Dividend ETF (DIVB) | |||
| GTOS | 24.57 | -0.11 | -0.45% |
| Invesco Short Duration Total Return Bond ETF (GTOS) | |||
| BASV | 30.23 | -0.14 | -0.47% |
| Brown Advisory Sustainable Value ETF (BASV) | |||
| CATG | 8.12 | -0.12 | -1.46% |
| Leverage Shares 2X Long CAT Daily ETF (CATG) | |||